Nearly 80% of Execs See ROI from Clinical Surveillance Tools
February 07, 2019 / Jessica Kent
Healthcare executives are generally seeing a return on investment (ROI) from their clinical surveillance tools, revealed a survey conducted by Sage Growth Partners (SGP) and commissioned by VigiLanz. However, some believe that solutions built into their electronic health records (EHRs) aren’t satisfying all their data analytics needs. Ninety-six percent of executives said they are using some sort of clinical surveillance solution, whether in-house, from a third-party, or as part of their EHR. Seventy-nine percent of executives said they believe there is ROI from clinical surveillance technology. Moreover, ninety-two percent said their clinical surveillance tools definitely or probably help them improve quality. Eighty-eight percent said that clinical surveillance is either extremely, very, or moderately important to their organization.